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The collective pharmaceutical procurement was launched in China in 2018 to reduce the prices of selected drugs, by pooling the demands of member cities and granting the contract to the manu-facturer with the lowest bid. We found the procurement significantly decreased the prices of most 
drugs. We also identified significant price increases on some drugs, indicating that manufacturers of these 
drugs may have strong market power to manipulate prices. The “winner-takes-all” principle applied in 
the procurement may further increase the market power of winning manufacturers by expanding their 
respective market shares. They may take the advantage of the market power to increase drug prices in the 
long-run. The continuously lowering price-caps may force the losing bidders to exit the market. A care-
ful assessment of the unintended consequences of the collective procurement is warranted.
In many provinces of China, hospitals and pharmacies have been conducting the group procurement of 
medicines since 2010s, to increase the bargaining power on price negotiation, as recommended by the 
then Ministry of Health, China. Provincial health authorities organized the group procurement and adopt-
ed price-caps to regulate the negotiations. While the public criticized the price-caps for being too high, 
the National Healthcare Security Administration launched in December 2018 a nationwide collective 
pharmaceutical procurement pilot trial with lower price-caps, coded as “4 + 7”, where the demands for a 
certain drug of member cities across China were pooled and granted to the manufacturer with the lowest 
bid, if it was below the price-cap [1]. The code “4 + 7” comes from the initial group of cities that include 
four provincial-level metropolitans (Beijing, Shanghai, Tianjin, and Chongqing) and seven major cities 
(Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi’an).
To investigate the impact of the “4 + 7” procurement, we compared the list 
of medicines in the procurement plan and the final contracted list to assess 
the completion of the procurement. We then retrieved the prices of the 
contracted drugs in Shanghai before and after the procurement, to com-
pare the price change [2]. We also collected the sales volumes of the man-
ufacturers who gained the “4 + 7” contracts before 2018 as additional back-
ground information [3]. Shanghai was chosen for this analysis because of 
better data transparency and availability compared with other member 
cities. Since the previous procurement of drugs were contracted at differ-
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Collective pharmaceutical pro-
curement with price-caps can de-
crease drug prices on average. But 
the continuously lowering price-
caps may force the losing compa-
nies to exit the market.
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ent prices in different batches before the “4 + 7” pilot, we weighted the pric-
es of each drug per batch by the purchased amounts to construct a weight-
ed average composite price. The composite price was then compared with 
the agreement price in the “4 + 7” procurement (Table 1).
Negotiation for 25 out of 31 drugs successfully resulted in a contract price, 
indicating a completion rate of 81%. The demand and supply sides failed to 
achieve an agreement on the remaining 6 drugs (ie, Amoxicillin, Azithromy-
cin tablet, Tramadol, Alfacalcidol, Captopril, Azithromycin injection). We 
were able to retrieve the prices of 24 medications among the contracted ones 
except Dexmedetomidine, and found that the prices of 21 medications decreased, with a range from 
−11.6% to −97.8%. On the contrary, the prices of three drugs (ie, Enalapril, Pemetrexed, and Flurbipro-
fen) increased by 150.4%, 139.4%, and 71.3%, respectively. The weighted average of price change for 
the 24 medications was −40.0%.
The collective medical procurement decreased the drug prices significantly on average. However, we found 
that, in six cases of the 24 contracted medications (ie, Entecavir, Olanzapine, Fosinopril, Lisinopril, Enal-
april, Flurbiprofen), the contract was obtained by the manufacturer with biggest market share (ie, largest 
sales volume proportion) in a separate market before 2018 (Table 1). In some other cases, major manu-
facturers (eg, Huahai, Jingxin, Beite, Hansoh) obtained several contracts for multiple products. For ex-
ample, Huahai gained contracts for Irbesartan, Paroxetine, Risperidone, Irbesartan/Hydrochlorothiazide, 
Lisinopril, and Losartan. Therefore, the impacts of the collective procurement need to be further evalu-
The “winner-takes-all” principle 
may increase the market power 
of winning manufacturers. Win-
ners may take the advantage of 
the market power to increase 
the drug prices in the long run.
Table 1. Drug price change due to the “4 + 7” collective pharmaceutical procurement and associated providers.
No. Drug Format Price beFore 4 + 7 (cNY, uSD) *
4 + 7 coNtract Price, 
(cNY, uSD)†
Price 
chaNge
coNtractor‡ market 
Share§, %
market 
Share raNk‖
1 Atorvastatin Tablet ¥5.00, $0.76 ¥0.94, $0.14 -81.1% Jialin 17.42 2
2 Rosuvastatin Tablet ¥5.98, $0.90 ¥0.78, $0.12 -87.0% Jingxin 6.91 3
3 Clopidogrel Tablet ¥3.68, $0.56 ¥3.18, $0.48 -13.6% Salubris 30.13 2
4 Irbesartan Tablet ¥3.04, $0.46 ¥0.20, $0.03 -93.4% Huahai 0.61 11
5 Amlodipine Tablet ¥1.88, $0.28 ¥0.15, $0.02 -92.1% Jingxin 0.02 23
6 Entecavir Tablet ¥28.06, $4.24 ¥0.62, $0.09 -97.8% Chia Tai-Tianqing 44.22 1
7 Escitalopram Tablet ¥13.94, $2.11 ¥4.42, $0.67 -68.3% KELUN 9.93 3
8 Paroxetine Tablet ¥4.26, $0.64 ¥1.67, $0.25 -60.8% Huahai 41.47 2
9 Olanzapine Tablet ¥24.03, $3.63 ¥9.64, $1.46 -59.9% Hansoh 59.99 1
10 Cefuroxime Tablet ¥0.60, $0.09 ¥0.51, $0.08 -14.2% Beite 2.63 7
11 Risperidone Tablet ¥3.24, $0.49 ¥0.17, $0.03 -94.8% Huahai 5.73 6
12 Gefitinib Tablet ¥63.00, $9.52 ¥54.70, $8.26 -13.2% Qilu Hainan 11.45 2
13 Fosinopril Tablet ¥2.80, $0.42 ¥0.84, $0.13 -69.9% Squibb 82.81 1
14 Irbesartan/Hydrochlorothiazide Tablet ¥4.40, $0.66 ¥1.09, $0.16 -75.2% Huahai 4.72 4
15 Lisinopril Tablet ¥0.26, $0.04 ¥0.23, $0.03 -11.6% Huahai 35.68 1
16 Tenofovir Tablet ¥6.67, $1.01 ¥0.59, $0.09 -91.1% Beite 4.02 3
17 Losartan Tablet ¥5.60, $0.85 ¥1.05, $0.16 -81.3% Huahai 6.57 3
18 Enalapril Tablet ¥0.22, $0.03 ¥0.56, $0.08 150.4% Yangzijiang 76.58 1
19 Levetiracetam Tablet ¥3.78, $0.57 ¥2.40, $0.36 -36.5% Jingxin 0.43 3
20 Imatinib Tablet ¥45.00, $6.80 ¥10.40, $1.57 -76.9% Hansoh 12.35 2
21 Montelukast Tablet ¥6.40, $0.97 ¥3.88, $0.59 -39.4% Minsheng 2.71 4
22 Montmorillonite Granule ¥1.84, $0.28 ¥0.68, $0.10 -63.1% Simcere 3.71 3
23 Pemetrexed Injection ¥1160.20, $175.26 ¥2776.97, $419.48 139.4% Huiyu 4.28 4
24 Flurbiprofen Injection ¥12.82, $1.94 ¥21.95, $3.32 71.3% Tide 98.33 1
*CNY, Chinese Yuan (¥). USD, US Dollar ($). Composite price per unit before “4 + 7” procurement, converted to 2018 CNY and USD according to cur-
rency exchange rate and consumer price index (CPI).
†Composite price per unit in “4 + 7” contract, converted to 2018 CNY and USD according to currency exchange rate and CPI.
‡Beite, Chengdu Beite Pharmaceutical Industry. Chia Tai-Tianqing, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd Hansoh, Jiangsu Hansoh phar-
maceuticals. Huahai, Zhejiang Huahai Pharmaceutical Co., Ltd Huiyu, Sichuan Huiyu Pharmaceutical Limited. Jialin, Beijing Jialin Pharmaceutical In-
dustry Company Limited. Jingxin, Zhejiang Jingxin Pharmaceutical Co. Ltd KELUN, Sichuan KELUN PHARMACEUTICAL Co., Ltd Minsheng, Hang-
zhou Minsheng Binjiang Pharmaceuticals. Qilu Hainan, Qilu Pharmaceutical Hainan Co., Ltd Salubris, Shenzhen Salubris Pharmaceuticals. Simcere, 
Hainan Simcere Pharmaceuticals. Squibb, Sino-American Shanghai Squibb Pharmaceuticals Ltd Tide, Beijing Tide Pharmaceutical Co., Ltd Yangzijiang, 
Yangzijiang Pharmaceuticals.
§Market share, sales volume proportion of contractor in the separate drug market.
‖Market share rank, the rank of sales volume of contractor in the separate drug market.
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ated carefully for three reasons. First, the collective procurement applies a “winner-takes-all” principle, 
which may increase the market power of the winning manufacturers in each drug market. A manufactur-
er with market power close to monopoly will in turn weaken the bargaining power of hospitals and phar-
macies in the long run [4]. The monopoly power may impede government’s attempt to reach an agreed 
contract at a low price which may result in same or even higher drug prices. In contrast to the “winner-
takes-all” principle, state Medicaid agencies in the US have managed the market by awarding contracts 
to more than one provider, carving up markets in regions to ensure all qualified parties shared in the con-
tracts [5].
Second, continuously lowering the price-cap levels may force some manufacturers to exit from the mar-
ket, especially the firms producing generic drugs [6]. In Canada, generic manufacturers became more 
likely to exit market when the price-caps were set at 25% of the brand-name product prices in 2010 than 
when the price-caps at 70% of brand-name prices in late 1990s [6]. Although market entries and exits 
result from market competition regularly, forced exits are a concern because it may lead to a loss of con-
sumer welfare in the long term. A good example is that US Food and Drug Administration (FDA) prom-
ulgated laws to attract more generic providers by expediting the review of generic drug applications and 
reducing the dominance of brand-name manufacturers that hinders market competition [7]. We notice 
that some manufacturers in previous provincial procurements did not participate in the “4 + 7”. Though 
we do not have access to the information that may explain the exits and do not know whether the exits 
are temporary, government need to be cautious of forced exits of generic manufacturers due to continu-
ously lowered price-caps.
Third, manufacturer participants in the procurement may sacrifice some revenues to become the “win-
ners” on certain drugs. Consequently, they may have the incentives to increase the prices of other medical 
products (eg, drugs or active pharmaceutical ingredients) that are not covered by the National Essential 
Medicines List or public funded health insurance to make up their loss in “4 + 7”. Strong price control of 
drug manufacturers will naturally lead to market-dominance behaviors [8]. The market-dominance be-
haviors may indirectly or directly increase the health expenditures by payers or patients.
Hence, while collective drug procurement is an important policy tool, its long-term impact may need to 
be carefully assessed and accounted for in policymaking.
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